Loading…
Loading…
can you talk about the sizing of that opportunity given the dirt that's systemic options
Can you talk to uptake of the [ VYALEV ] and specifically what you're seeing regarding competitive dynamics
Can you talk about the extent to which the underlying IgG related disease population is larger than what literature has suggested historically and what that means for the underlying opportunity.
Can you talk to the extent to which there's been pent-up demand here? Give us your refreshed views on the sales opportunity here?
what is your appetite for significant consequential M&A regarding rare diseases? And what is your appetite in general for continuing to build out that broad therapeutic vertical?
what's it going to take to see an inflection here? Or maybe put differently, do you think there has to be some externality like the availability of a subcu form to get the product really moving again?
KRYSTEXXA, how are you thinking about the growth runway there and the potential for biosimilar down the road? And then also how you're thinking about the competitive landscape for TEPEZZA?